NCT02889016 Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS
| NCT ID | NCT02889016 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Pediatric Acute-Onset Neuropsychiatric Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2013-03 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2013-03 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is an investigation of the neurologic, immunologic, and rheumatologic markers of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a condition characterized by the abrupt, dramatic onset of obsessive compulsive disorder (OCD) and/or eating restriction accompanied by equally abrupt and severe co-morbid neuropsychiatric symptoms, which include anxiety, emotional lability, depression, irritability, aggression, oppositionality, deterioration in school performance, behavioral (developmental) regression, sensory amplification, movement abnormalities, sleep disturbance, and urinary frequency. PANS is thought to be caused by infection, inflammation, or alternate triggers that is associated with a brain response that leads to these symptoms. The purpose of this study is to examine specific neurologic, immunologic, rheumatologic, and genomic, components in children with the acute-onset of psychiatric symptoms. This research may begin to uncover a much larger story of autoimmune processes that are involved in psychiatric disorders of childhood. By better understanding the etiologic components of psychiatric phenomenon, future treatments may be better targeted to underlying causes.
Eligibility Criteria
Inclusion Criteria: * Children with PANS 1. Age 1-18 at onset of PANS 2. Diagnosis of PANS: abrupt onset of OCD or food restriction, and at least two of the following associated symptoms: frequent urination, worsening handwriting/cognition, inattention, anorexia, separation anxiety, oppositionality, irritability/rage outbursts, and emotional lability. 3. Patients must live within 90 miles of Stanford University and have a new onset of PANS illness 4. Patients must have an established pediatrician within 90 miles of Stanford University for 3 years. * Healthy Controls 1. Age 4-18 2. No psychiatric diagnosis Exclusion Criteria: * Any neuropsychiatric illness that may obscure the clear diagnosis of PANS
Contact & Investigator
Joanne Cheung
✉ pansresearch@stanford.eduFrequently Asked Questions
Who can join the NCT02889016 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 18 Years, studying Pediatric Acute-Onset Neuropsychiatric Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02889016 currently recruiting?
Yes, NCT02889016 is actively recruiting participants. Contact the research team at pansresearch@stanford.edu for enrollment information.
Where is the NCT02889016 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT02889016 clinical trial?
NCT02889016 is sponsored by Stanford University. The trial plans to enroll 500 participants.